CCM
RPRX icon

Conway Capital Management’s Royalty Pharma RPRX Stock Holding History

Conway Capital Management’s Portfolio RPRX Stock Details RPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-9,765
Closed -$352K – 48
2023
Q1 		$352K Sell
9,765
-839
-8% -$31.1K 0.29% 33
2022
Q4 		$419K Buy
10,604
+10
+0.1% +$417 0.42% 29
2022
Q3 		$426K Sell
10,594
-241
-2% -$10.3K 0.38% 31
2022
Q2 		$456K Buy
10,835
+10
+0.1% +$410 0.41% 32
2022
Q1 		$422K Buy
+10,825
New +$425K 0.27% 38

Other funds holding RPRX

Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Conway Capital Management's RPRX Position: Q2 2023 in Review

Conway Capital Management sold out of Royalty Pharma (RPRX) in Q2 2023, closing a stake of 9,765 shares — an estimated $352K sold.

Conway Capital Management first reported a position in RPRX in Q1 2022 and held it in 5 quarters. The position peaked at $456K in Q2 2022. 325 funds tracked by Wall St. Rank hold RPRX as of Q2 2023.

  • Conway Capital Management reported no remaining Royalty Pharma position as of Q2 2023 after selling out during the quarter.
  • Conway Capital Management sold 9,765 Royalty Pharma shares in Q2 2023, an estimated $352K.
  • Conway Capital Management first reported a position in Royalty Pharma in Q1 2022 and held it in 5 quarters.
  • Conway Capital Management's Royalty Pharma position peaked at $456K in Q2 2022.
  • 325 funds tracked by Wall St. Rank held Royalty Pharma as of Q2 2023.

Based on Conway Capital Management's 13F filing for Q2 2023, filed 3 Dec 2024.